[Jackie07]

Cathy,

Found these two abstracts related to the treatment of tumors in the lung. Might be worth a discussion with your oncologist.

Gan To Kagaku Ryoho. 2015 Aug;42(8):973-80.
[Results of a Special Drug Use-Results Survey on Compliance to Tegafur/Uracil(UFT)Adjuvant Chemotherapy for Non-Small Cell Lung Cancer].
[Article in Japanese]
Koyama T1, Funato Y, Yamaguchi Y, Oda M, Ito K.
Author information
Abstract
We report the results of a special drug use-results survey that used medication diaries about compliance to tegafur/uracil (UFT) adjuvant chemotherapy in patients who had undergone complete resection for non-small cell lung cancer. Between April1 , 2008, and March 31, 2010, 2,527 patients were enrolled. Of these patients, 2,411 and 1,811 were evaluated for treatment and compliance, respectively. The 2-year treatment completion rate was 59.1% in 2,093 of the 2,411 patients, excluding 318 patients with treatment failure owing to recurrence. The results were comparable with those from The Japan Lung Cancer Research Group on PostsurgicalAdjuvant Chemotherapy (JLCRG). The main reasons of the treatment failure were gastrointestinaland hepatic disorders. The proportion of patients with @75% compliance was 95.3% (1,726/1,811), and most of the patients who kept their medication diaries exhibited good compliance.

-------------------------

Gan To Kagaku Ryoho. 2003 Jun;30(6):879-82.[A case of recurrent breast cancer with lung metastasis and overexpression of HER2 that responded to UFT and cyclophosphamide combination therapy after sequential treatments with epirubicin, taxanes, and trastuzumab].
[Article in Japanese]
Nishimura R1, Nagao K, Miyayama H, Okazaki S, Nakagawa K, Fujimura Y.
Author information
Abstract
We describe a 57-year-old woman who underwent modified mastectomy for right breast cancer (T2N0M0) with overexpression of HER2, in whom lungmetastasis developed 3 years after operation. She received sequential chemotherapy, including epirubicin plus cyclophosphamide, docetaxel, paclitaxel and trastuzumab, but the lung lesion progressed after transiently showing a partial response. Oral treatment with UFT and cyclophosphamide was begun as fifth-line treatment. The lung tumor shrank after 2 months, and a partial response has been maintained during continued treatment with UFT and cyclophosphamide. No adverse effects have occurred. We regard combination therapy with oral UFT and cyclophosphamide to be useful for the management of metastatic breast cancer, even in heavily pretreated cases with overexpression of HER2.